Edesa Biotech Net Worth
Edesa Biotech Net Worth Breakdown | EDSA |
Edesa Biotech Net Worth Analysis
Edesa Biotech's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Edesa Biotech's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Edesa Biotech's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Edesa Biotech's net worth analysis. One common approach is to calculate Edesa Biotech's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Edesa Biotech's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Edesa Biotech's net worth. This approach calculates the present value of Edesa Biotech's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Edesa Biotech's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Edesa Biotech's net worth. This involves comparing Edesa Biotech's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Edesa Biotech's net worth relative to its peers.
Enterprise Value |
|
To determine if Edesa Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Edesa Biotech's net worth research are outlined below:
| Edesa Biotech generated a negative expected return over the last 90 days | |
| Edesa Biotech has high historical volatility and very poor performance | |
| Net Loss for the year was (8.37 M) with profit before overhead, payroll, taxes, and interest of 311.2 K. | |
| Edesa Biotech currently holds about 12.81 M in cash with (6.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83. | |
| Edesa Biotech has a frail financial position based on the latest SEC disclosures | |
| Roughly 33.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: EDSA stock touches 52-week low at 2.27 amid market challenges - Investing.com UK |
Edesa Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Edesa Biotech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Edesa Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 9th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of December 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Know Edesa Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Edesa Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Edesa Biotech backward and forwards among themselves. Edesa Biotech's institutional investor refers to the entity that pools money to purchase Edesa Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Global Retirement Partners, Llc. | 2024-09-30 | 25.0 | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 19.0 | Bank Of America Corp | 2024-06-30 | 18.0 | Ubs Group Ag | 2024-06-30 | 4.0 | Crédit Agricole S.a. | 2024-06-30 | 1.0 | Allsquare Wealth Management Llc | 2024-09-30 | 1.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Fmr Inc | 2024-06-30 | 0.0 | Cm Management, Llc | 2024-09-30 | 110 K | Geode Capital Management, Llc | 2024-06-30 | 18.2 K | Vanguard Group Inc | 2024-09-30 | 15.9 K |
Follow Edesa Biotech's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.14 M.Market Cap |
|
Project Edesa Biotech's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.44) | (0.46) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (1.10) | (1.15) |
When accessing Edesa Biotech's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Edesa Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Edesa Biotech's profitability and make more informed investment decisions.
Please note, the presentation of Edesa Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Edesa Biotech's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Edesa Biotech's management manipulating its earnings.
Evaluate Edesa Biotech's management efficiency
Edesa Biotech has return on total asset (ROA) of (0.7152) % which means that it has lost $0.7152 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2929) %, meaning that it created substantial loss on money invested by shareholders. Edesa Biotech's management efficiency ratios could be used to measure how well Edesa Biotech manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.61. In addition to that, Return On Capital Employed is expected to decline to -0.46. At present, Edesa Biotech's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 209.5 K, whereas Total Assets are forecasted to decline to about 8.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 42.65 | 44.66 | |
| Tangible Book Value Per Share | 42.65 | 43.64 | |
| Enterprise Value Over EBITDA | (100.62) | (95.59) | |
| Price Book Value Ratio | 109.59 | 115.07 | |
| Enterprise Value Multiple | (100.62) | (95.59) | |
| Price Fair Value | 109.59 | 115.07 | |
| Enterprise Value | 955.1 M | 1 B |
Leadership at Edesa Biotech emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Enterprise Value Revenue 128.5 K | Revenue 500 | Quarterly Revenue Growth (1.00) | Return On Equity (1.29) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Edesa Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Edesa Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Edesa Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Edesa Biotech Corporate Filings
F4 | 12th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 3rd of June 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 31st of May 2024 Other Reports | ViewVerify |
Edesa Biotech Earnings per Share Projection vs Actual
Edesa Biotech Corporate Management
| CPA CPA | Chief Officer | Profile | |
| BA CPA | Chief Officer | Profile | |
| Dr MBA | President | Profile | |
| Gary Koppenjan | VP Communications | Profile | |
| MD FRCPC | Company CEO | Profile | |
| Rajan Puri | VP Manufacturing | Profile | |
| BA CA | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.78) | Quarterly Revenue Growth (1.00) | Return On Assets (0.72) | Return On Equity (1.29) |
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.